MedTrace Logo

Clinical Trial to Evaluate the Efficacy and Safety of 'Pelubiprofen Controlled Released Tab.' in Acute Traumatic Injury

NCT03874247 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2019-03-19

No results posted yet for this study

Summary

A randomized, double-blind, placebo-controlled, parallel, multi-center phase III clinical trial

Conditions

  • Acute Traumatic Injury

Interventions

DRUG

pelubiprofen 45mg

bid for 3 days after meal

DRUG

pelubiprofen placebo

bid for 3 days after meal

Sponsors & Collaborators

  • Daewon Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-25
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03874247 on ClinicalTrials.gov